Ibudilast ameliorates experimentally induced colitis in rats via down-regulation of proinflammatory cytokines and myeloperoxidase enzyme activity

Objectives: This study was carried out to explore the possible anti-inflammatory effect of ibudilast on acetic acid-induced colitis in rats. Methods: Fifty adult Wistar rats were separated into 5 groups, including the control group, acetic acid group, acetic acid + vehicle, acetic acid + sulfasalazine (100 mg/kg/day)group, and acetic acid + ibudilast (30 mg/kg/day) group. Colitis was induced in rats by the inter-rectal installation of 2 ml of 4% (v/v) acetic acid. Sulfasalazine and ibudilast were administered orally for ten days after 2 hours of induction. Results: The treatment with ibudilast significantly reduced disease activity index (DAI), macroscopic colonic scores (MAC), and histopathological changes induced by acetic acid. Also, ibudilast markedly decreased the expression of proinflammatory markers (TNF-α and IL-1β) in colonic tissue. Moreover, ibudilast inhibited myeloperoxidase (MPO) enzyme activity that was increased by acetic acid. Conclusion: Therefore, ibudilast may have a therapeutic effect in the management of ulcerative colitis

Study the topical effect of six days use of different lycopene doses on imiquimod-induce psoriasis-like skin inflammation in Mice

Lycopene is a hydrocarbon phytochemical that is present in red vegetables and fruits, several studies reviewed the pharmacological properties of Lycopene across years ago and in different aspects including inflammation, cardiovascular disease, prostatic cancer and different dermatological complaints. Objective: we investigated the potential impact of two different doses of topical Lycopene and as add on therapy to Clobetasol on Psoriasis model that induced by Imiquimod in mice. Methods: This was accomplished by dividing 48 mice into six groups (8 mice per each group). All groups received Imiquimod for induction of Psoriasis (except Group I which is healthy group) across the experiment days. Group II (Induction group) received Petrolatum gel (Vaseline) for six days after 6 days induction period with Imiquimod. The rest groups III, IV,V,VI received Clobetasol propionate 0.05%, 0.125 mg/ml Lycopene, 0.25 mg/ml Lycopene and combination of 0.25 mg/ml Lycopene and 0.05% Clobetasol propionate ointments respectively once daily for six days after 6 days of induction period with Imiquimod